Bristol-Myers Squibb (BMS) is a global pharmaceutical company known for its innovative treatments in oncology, cardiovascular, and immunology. The company has demonstrated a commitment to sustainability through its efforts to reduce carbon emissions and improve the environmental impact of its operations. Bristol-Myers Squibb’s ESG rating reflects its strong focus on patient access to medicine and its investments in research and development. However, the company faces challenges related to drug pricing and its impact on healthcare affordability, particularly in developing regions. Additionally, concerns have been raised about corporate governance and ethical issues regarding its product pricing practices. For more insights, consult the latest Bristol-Myers Squibb ESG report, which balances its innovations in healthcare with the ongoing challenges it faces.